Quanterix (QTRX) said Monday that its Simoa p-Tau 217 Planar Kit for Alzheimer's Disease testing is now commercially available for clinical research use.
The blood test kit combines Eli Lilly's (LLY) p-Tau 217 antibody technology and Quanterix' SP-X platform.
Shares of Quanterix were down more than 5% in after-hours activity.
Price: 12.28, Change: -0.68, Percent Change: -5.28
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.